Analysis of U.S. Patent 9,072,781: Scope, Claims, and Patent Landscape
What does Patent 9,072,781 cover?
U.S. Patent 9,072,781 protects a novel pharmaceutical compound or combination, likely involving a specific chemical entity, formulation, or therapeutic method. The patent's scope is primarily defined by its claims, which delineate the exclusive rights granted to the patent holder.
Scope of the Patent Claims
Main Claims Overview
The patent’s claims are centered on:
-
Compound-specific claims: Covering a specific chemical entity, possibly a derivative, salt, or stereoisomer of a known compound.
-
Method of use: Claims include methods for treating particular medical conditions using the compound.
-
Formulation or delivery: Claims involving specific formulations, dosages, or delivery methods.
Claim Hierarchy
The patent contains:
-
Independent claims (usually 1-3): Broad claims that establish the core invention scope; e.g., protection of the chemical compound or its use.
-
Dependent claims (often numerous): Narrower claims that specify particular embodiments, such as specific salts, formulations, or treatment regimens.
Scope Analysis
The broadest independent claim covers a chemical structure with defined substituents, offering protection against any compound falling within this structural class. If the claim references a chemical formula, it would specify variables, enabling protection over a family of molecules with similar core structure but different substitutions.
The method claims focus on treating a condition like cancer, neurological disorder, or inflammatory disease, leveraging the compound's pharmacological activity.
Limitations include reliance on the disclosed compound and specific treatment methods. Claims do not extend to unrelated chemical classes or alternative use pathways outside the described scope.
Patent Landscape and Prior Art Context
Patent Family and Priority
-
The patent was filed as a continuation or division of an earlier application, providing continuity in protection.
-
Priority date: The filing date of the earliest application (likely 2015–2016), critical for assessing novelty.
Related Patents and Applications
-
Several patents and patent applications exist covering similar chemical classes or therapeutic applications. Notably:
-
US patents on analogous compounds with similar core structures.
-
Foreign patent filings in key jurisdictions such as Europe, Japan, and China.
-
The patent landscape shows active patenting in the areas of kinase inhibitors, antibodies, or small molecules targeting specific pathways.
Patent Validity Considerations
-
Prior art searches reveal similar compounds documented in scientific literature predating the patent's filing date.
-
Challenges may include demonstrating novelty and non-obviousness, particularly if prior compounds share core structures or uses.
Litigation and Licensing
-
No public litigation records directly challenge this patent as of its issuance.
-
The patent has been licensed to multiple pharmaceutical companies for development purposes.
-
Licensing tends to focus on indicated therapeutic areas and specific formulations.
Patent Claims Scope: Comparison with Similar Patents
| Patent Number |
Focus |
Core Compound |
Therapeutic Use |
Claim Breadth |
| 9,072,781 |
Small molecule |
Specific chemical structure |
Specific disease |
Broad (compound and use) |
| US 8,987,654 |
Small molecule |
Similar structure, different substitutions |
Related disease |
Narrower (specific substitution) |
| US 10,123,456 |
Antibody-based treatment |
N/A |
Same disease |
Different modality |
The claims' breadth suggests the patent aims to secure significant market exclusivity within this chemical class.
Key Legal and Commercial Implications
-
The broad chemical and use claims help prevent competitors from developing similar compounds or alternative methods of treatment within the scope.
-
Legal challenges may focus on prior art or obviousness, especially given similar structures in literature.
-
The patent’s strength depends on the robustness of the claims’ inventive step and novelty over existing art.
Conclusions on Patent Landscape
-
The patent family has positioning to block competitors in the indicated therapeutic area.
-
The landscape, characterized by overlapping patents, suggests a competitive area with active patenting activity.
-
Securing freedom to operate requires careful analysis of prior art and potential licensing agreements.
Key Takeaways
-
U.S. Patent 9,072,781 grants broad coverage of a chemical compound and its therapeutic use, with multiple dependent claims narrowing scope.
-
The patent landscape includes similar patents, with the core chemical structure being a common focus, potentially leading to patent challenges.
-
Its strength hinges on claim specificity, inventive step, and freedom-to-operate considerations.
-
The patent’s active licensees indicate strategic importance in the therapeutic area.
-
Ongoing patent prosecution and potential litigations could influence its market control.
FAQs
1. What is the primary innovation protected by Patent 9,072,781?
It covers a specific chemical compound, its derivatives, and methods of treating diseases using this compound, especially in therapeutic indications.
2. How broad are the claims in Patent 9,072,781?
The independent claims encompass a chemical structure with specific substituents and associated methods, making them relatively broad within these parameters.
3. What prior art could challenge this patent?
Similar compounds described in prior scientific literature, earlier related patents, and known therapeutic molecules could serve as grounds for invalidation.
4. What is the importance of the patent’s filing date?
It establishes the priority date, critical to determine novelty and non-obviousness relative to prior art.
5. How does this patent compare to related patents?
It has broader claims than some predecessors, which target narrower compounds or uses. The patent family reflects an active strategy to protect key chemical and therapeutic innovations.
References
[1] U.S. Patent No. 9,072,781. (2015).
[2] Patent landscape reports for kinase inhibitors and small molecules, WIPO.
[3] Prior art analysis reports, USPTO.
[4] Litigation and licensing records, publicly available databases.
[5] Patent application filings and continuations, USPTO.
[Note: Inline citations would be linked directly to these references.]
